What is CytoDyn based on?

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play…

Who is Cytodyn Inc?

The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington. Trailing total returns as of 6/3/2024, which may include dividends or other distributions. Benchmark is

Does CytoDyn have a webcast?

CytoDyn Announces Webcast to Provide Company Update GlobeNewswireThu, Dec. 07, 2023 See All Press Releases » CYDY Income Statement Revenue (TTM) 0.00 Revenue Per Share 0.00 Gross Profit (TTM) 0.00 EBITDA (TTM) -15.17M Net Income (TTM) -51.69M EPS Diluted (TTM) -$0.06 Full Income Statement » CYDY Balance Sheet Total Cash (MRQ) 1.40M